Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease

Preya Patel, David Smith, Jason P. Connor, Leigh U. Horsfall, Kelly L. Hayward, Fabrina Hossain, Suzanne Williams, Tracey Johnson, Katherine Stuart, Nigel N. Brown,

Canadian Journal of Gastroenterology and Hepatology · 2017 · 22 citations · 29 references

DOIFull text

Open access

Concepts

Abstract

Aim . To examine the association between lifetime alcohol consumption and significant liver disease in type 2 diabetic patients with NAFLD. Methods . A cross-sectional study assessing 151 patients with NAFLD at risk of clinically significant liver disease. NAFLD fibrosis severity was classified by transient elastography; liver stiffness measurements ≥8.2 kPa defined significant fibrosis. Lifetime drinking history classified patients into nondrinkers, light drinkers (always ≤20 g/day), and moderate drinkers (any period with intake &gt;20 g/day). Result . Compared with lifetime nondrinkers, light and moderate drinkers were more likely to be male (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn fontstyle="italic">0.008</mml:mn></mml:math>) and to be Caucasian (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn fontstyle="italic">0.007</mml:mn></mml:math>) and to have a history of cigarette smoking (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M3"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn fontstyle="italic">0.000</mml:mn></mml:math>), obstructive sleep apnea (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M4"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn fontstyle="italic">0.003</mml:mn></mml:math>), and self-reported depression (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M5"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn fontstyle="italic">0.003</mml:mn></mml:math>). Moderate drinkers required ≥3 hypoglycemic agents to maintain diabetic control (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M6"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn fontstyle="italic">0.041</mml:mn></mml:math>) and fibrate medication to lower blood triglyceride levels (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M7"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn fontstyle="italic">0.044</mml:mn></mml:math>). Compared to lifetime nondrinkers, light drinkers had 1.79 (95% CI: 0.67–4.82; <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M8"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn fontstyle="italic">0.247</mml:mn></mml:math>) and moderate drinkers had 0.91 (95% CI: 0.27–3.10; <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M9"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn fontstyle="italic">0.881</mml:mn></mml:math>) times the odds of having liver stiffness measurements ≥8.2 kPa (adjusted for age, gender, and body mass index). Conclusions . In diabetic patients with NAFLD, light or moderate lifetime alcohol consumption was not significantly associated with liver fibrosis. The impact of lifetime alcohol intake on fibrosis progression and diabetic comorbidities, in particular obstructive sleep apnea and hypertriglyceridemia, requires further investigation.

References

29